Appili Therapeutics Inc. (TSX: APLI)
Canada
· Delayed Price · Currency is CAD 0.0350
0.00 (0.00%)
Jul 18, 2024, 2:59 PM EDT
Appili Therapeutics Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Year Ending | TTM | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.83 | 0.83 | 0.33 | 1.39 | - | 0.2 | Upgrade
|
| Revenue Growth (YoY) | 147.60% | 147.60% | -75.97% | - | - | - | Upgrade
|
| Gross Profit | 0.83 | 0.83 | 0.33 | 1.39 | - | 0.2 | Upgrade
|
| Selling, General & Admin | 3.26 | 3.26 | 4.62 | 5.32 | 5.44 | 4.25 | Upgrade
|
| Research & Development | 5.62 | 5.62 | 3.62 | 20.74 | 10.22 | 2.08 | Upgrade
|
| Operating Expenses | 8.88 | 8.88 | 8.25 | 26.07 | 15.66 | 6.33 | Upgrade
|
| Operating Income | -8.05 | -8.05 | -7.91 | -24.68 | -15.66 | -6.13 | Upgrade
|
| Interest Expense | -1.63 | -1.63 | -0.95 | -1.55 | -0.12 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.02 | 0.02 | 0.03 | 0.03 | 0.12 | 0.04 | Upgrade
|
| Net Interest Expenses | -1.61 | -1.61 | -0.92 | -1.52 | -0.01 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.07 | 0.07 | -0.36 | 0.06 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 5.89 | 5.89 | 0.14 | 1.06 | 1.34 | 0.69 | Upgrade
|
| EBT Excluding Unusual Items | -3.71 | -3.71 | -9.06 | -25.08 | -14.33 | -5.42 | Upgrade
|
| Other Unusual Items | - | - | -0.14 | - | - | - | Upgrade
|
| Pretax Income | -3.71 | -3.71 | -9.21 | -25.08 | -14.33 | -5.42 | Upgrade
|
| Income Tax Expense | 0.07 | 0.07 | 0.04 | 0.04 | - | - | Upgrade
|
| Net Income | -3.78 | -3.78 | -9.24 | -25.12 | -14.33 | -5.42 | Upgrade
|
| Net Income to Common | -3.78 | -3.78 | -9.24 | -25.12 | -14.33 | -5.42 | Upgrade
|
| Shares Outstanding (Basic) | 121 | 121 | 114 | 67 | 59 | 34 | Upgrade
|
| Shares Outstanding (Diluted) | 121 | 121 | 114 | 67 | 59 | 34 | Upgrade
|
| Shares Change (YoY) | 6.62% | 6.62% | 70.43% | 12.76% | 72.40% | 13.47% | Upgrade
|
| EPS (Basic) | -0.03 | -0.03 | -0.08 | -0.38 | -0.24 | -0.16 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.03 | -0.08 | -0.38 | -0.24 | -0.16 | Upgrade
|
| Free Cash Flow | -2.49 | -2.49 | -10.1 | -19.08 | -11.46 | -4.26 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.02 | -0.09 | -0.29 | -0.19 | -0.12 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | 100.00% | Upgrade
|
| Operating Margin | -972.94% | -972.94% | -2368.29% | -1774.56% | - | -3079.74% | Upgrade
|
| Free Cash Flow Margin | -301.44% | -301.44% | -3022.65% | -1372.07% | - | -2140.26% | Upgrade
|
| EBITDA | -8.04 | -8.04 | -7.91 | -24.67 | -15.65 | -6.11 | Upgrade
|
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | Upgrade
|
| EBIT | -8.05 | -8.05 | -7.91 | -24.68 | -15.66 | -6.13 | Upgrade
|
| Revenue as Reported | 0.84 | 0.84 | 0.36 | 1.42 | 0.12 | 0.24 | Upgrade
|
Source: S&P Capital IQ. Standard template.